Roivant Sciences ROIV
NASDAQ ROIV
$41.38 -0.10 (-0.25%)
As of: Sep 9, 2026 · 11:15 AM EDT

Roivant Sciences (ROIV) Other Non-Current Assets (2021 - 2026)

Roivant Sciences' (ROIV) quarterly Other Non-Current Assets came in at $29.6 million in Q2 2026, down 4.85% on a YoY basis from $31.1 million in Q2 2025, and down 27.69% quarter-over-quarter from $40.9 million in Q1 2026.

Analysis

Roivant Sciences (ROIV) Other Non-Current Assets (2021 - 2026) Analysis & Trends

Roivant Sciences (ROIV) has reported Other Non-Current Assets for 6 consecutive years, with $29.6 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Other Non-Current Assets fell 4.85% year-over-year to $29.6 million; the trailing twelve-month figure through Jun 2026 stood at $29.6 million (down 4.85% YoY), and the FY2026 full-year result was $40.9 million, up 24.52% from the prior year.
  • Other Non-Current Assets slipped to $29.6 million in Q2 2026 per ROIV's latest filing, from $40.9 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $320.2 million in Q3 2024 and bottomed at $11.9 million in Q3 2022.
  • Historically, Other Non-Current Assets has averaged $57.3 million across 5 years, with a median of $34.2 million in 2024.
  • The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets soared 543.1% in 2024, then sank 91.31% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $46.2 million in 2022, then rose by 1.35% to $46.8 million in 2023, then slipped by 27.68% to $33.9 million in 2024, then grew by 2.02% to $34.6 million in 2025, then fell by 14.4% to $29.6 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods registered $29.6 million, $40.9 million, and $34.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Amgen 211.68 Bn 197.69 Bn 7.24 Bn 12.98 Bn
2 Gilead Sciences 180.84 Bn 177.66 Bn 6.22 Bn 4.75 Bn
3 Vertex Pharmaceuticals 132.30 Bn 124.45 Bn 2.84 Bn 1.25 Bn
4 Regeneron Pharmaceuticals 82.50 Bn 74.50 Bn 3.93 Bn 2.31 Bn
5 Argenx Se 61.49 Bn 56.31 Bn 1.37 Bn 124.00 Mn
6 Moderna 55.01 Bn 49.87 Bn 52.00 Mn 618.00 Mn
7 Alnylam Pharmaceuticals 34.08 Bn 30.77 Bn 992.69 Mn 65.13 Mn
8 Biogen 31.35 Bn 30.06 Bn 1.96 Bn 831.80 Mn
9 Roivant Sciences 29.87 Bn 29.87 Bn 1.16 Mn 29.59 Mn
10 Insmed 27.84 Bn 26.68 Bn 358.27 Mn 104.44 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 29.59 Mn
Mar 31, 2026 40.92 Mn
Dec 31, 2025 34.56 Mn
Sep 30, 2025 27.83 Mn
Jun 30, 2025 31.09 Mn
Mar 31, 2025 32.86 Mn
Dec 31, 2024 33.88 Mn
Sep 30, 2024 320.24 Mn
Jun 30, 2024 32.81 Mn
Mar 31, 2024 156.27 Mn
Dec 31, 2023 46.85 Mn
Sep 30, 2023 49.80 Mn
Jun 30, 2023 46.31 Mn
Mar 31, 2023 49.48 Mn
Dec 31, 2022 46.22 Mn
Sep 30, 2022 11.87 Mn
Jun 30, 2022 14.25 Mn
Mar 31, 2022 25.82 Mn
Dec 31, 2021 20.88 Mn
Sep 30, 2021 21.34 Mn